CSRC halts the initial public offering from Aosaikang Pharmaceutical as its new shares are selling at a higher price than the industry average meanwhile its old shares have been overly transferred. This would directly affect China's securities market following the newly restart of IPO in 2014. ANBOUND research team thinks that the pricing issue should be determined by the market and lesser intervention by the CSRC would be better. The CSRC should keep a close eye on the market system and function to ensure it is sound, currently the top priority should be on restarting the IPO. The ulterior motive of Individual enterprise or organization should not become an obstacle for IPO lisitng.